Results 101 to 110 of about 3,302 (197)

Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study. [PDF]

Adv Ther
Tursi A, Pasta A, Elisei W, Barberio B, Mocci G, Savarino EV, de Barba C, Maconi G, Cataletti G, Scaldaferri F, Napolitano D, Costa F, Ceccarelli L, Marzo M, Monterubbianesi R, di Fonzo M, Lombardi G, Patturelli M, Ribaldone DG, Bertani L, Rodino' S, Sebkova L, Bodini G, Pranzo G, Serio M, Scarcelli A, Luppino I, Ferronato A, Spagnuolo R, Luzza F, Morano D, Gravina AG, Pellegrino R, Vespere G, Sedda S, Allegretta L, Fanigliulo L, Grossi L, Cortellini F, Forti G, Neve V, Piergallini S, Scarozza P, Bevevino G, Iacopini F, Capone P, Gaiani F, Kayali S, Mucherino C, D'antonio E, D'ascoli B, Colucci R, Bachetti F, Giorgetti GM, Clemente V, Pagnini C, Cuomo A, Donnarumma L, Onidi FM, Satta PU, Picchio M, Papa A, Italian Network for Inflammatory Bowel Diseases (IN-IBD).   +62 more
europepmc   +1 more source

Filgotinib for the Treatment of Small Bowel Crohn’s Disease: The DIVERGENCE 1 Trial

Gastroenterology, 2023
D'Haens, Geert R., Lee, Scott, Taylor, Stuart A., Serone, Adrian, Rimola, Jordi, Colombel, Jean-Frederic, Besuyen, Robin, Gecse, Krisztina, McKevitt, Matt, Reinisch, Walter, Ren, Xuehan, Schwartz, David   +11 more
openaire   +2 more sources

Indirect inhibition of the NLRP3-interleukin-1β axis contributes to the efficacy of JAK1 inhibitors in experimental colitis and human ulcerative colitis. [PDF]

Nat Commun
Liu B, Spalinger MR, Invernizzi A, Gerdes E, Steglich B, Schwarzfischer M, Machicote A, Pelczar P, Pöhlmann D, Nawrocki M, Böttcher M, Aleko A, Velasquez LN, Wende S, Stallbaum F, Neuendorff J, Grosshauser S, Muscate F, Douilhet G, Perez LG, Sabihi M, Möller K, Viehweger F, Sutter JP, Kilian C, Kumar Y, Fründt T, Sauter G, Rösch T, Gagliani N, Caflisch A, Scharl M, Huber S.   +32 more
europepmc   +1 more source

A multicentered retrospective cohort study comparing JAK inhibitor therapies in moderate-to-severe ulcerative colitis. [PDF]

Crohns Colitis 360
Kumar A, Baxter J, Rimmer P, Noble B, Bower J, Makki MU, Hatta A, Chikhlia A, Cheesbrough J, Disney B, Muir J, Karova M, Butterworth J, Sagar N, Al-Talib I, Nahal J, Ali N, Sagar V, Varyani F, Smith S, Bourne S, Hsu YK, Eltahir A, de Silva S, Harvey P.   +24 more
europepmc   +1 more source

JAK Inhibitors for Crohn's Disease: A Systematic Review and Dose-Response Network Meta-Analysis of Efficacy and Safety. [PDF]

JGH Open
Qtaishat FA, AlKayyat A, Yasin JA, A Tamimi MA, Tarawneh J, AlDaher L, Abdallah S, Alghaniem MMA, Abunamoos A, Musa A, Ateiwi YA, Taha Y, Tamimi TA.   +12 more
europepmc   +1 more source

Janus kinase inhibitor and rituximab in rheumatoid arthritis: is it a safe combination? [PDF]

Rheumatol Adv Pract
Rabee H, Mahto A.
europepmc   +1 more source

Safety and efficacy of different JAK inhibitors in the treatment of inflammatory bowel disease: a network meta-analysis. [PDF]

Front Pharmacol
Wu H, Zhou Y, Chen X, Wang L, Guo Y, Du X, Miao X.   +6 more
europepmc   +1 more source

A meta-analysis of the efficacy and safety of Janus kinase inhibitors in patients with ulcerative colitis. [PDF]

Medicine (Baltimore)
Yang Q, Yan Y.
europepmc   +1 more source

Safety and efficacy of long-term filgotinib treatment in Japanese patients with ulcerative colitis: an interim subgroup analysis of the SELECTION long-term extension study. [PDF]

Crohns Colitis 360
Matsuoka K, Hata E, Kaise T, Rudolph C, Hibi T.   +4 more
europepmc   +1 more source

Real-World Comparative Efficacy and Safety of Upadacitinib, Tofacitinib, and Filgotinib in Patients With Ulcerative Colitis. [PDF]

Cureus
Ahmad F, Hussain T, Gunaratne CH, Collum J, Ghaffar A, Gharbia K.   +5 more
europepmc   +1 more source